Resources

Interview: Accelerating advanced therapy pipelines and viral vector commercialisation

  In January, Phacilitate Leaders World & World Stem Cell Summit 2020 brought together the entire ecosystem of the advanced therapies industry from all corners of the globe to continue to build strong partnerships and collaborations to Miami, FL.  Phacilitate team spoke to Felix Hsu, Senior Vice President and Global Head at WuXi Advanced Therapies about strategically looking …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW

BioProcess International Ask The Expert special featured article on AAV

  This article features: Bai-wei Gu, Head of the Cell Line Development Group, Juan Lagos, Head of Upstream Processing, and Matthew Weaver, Head of Downstream Processing at WuXi Advanced Therapies covering how to accelerate development and manufacturing platforms for viral vectors. Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW

BIO 2019 recognizes WuXi AppTec

WuXi AppTec’s enabling capabilities and contribution to the development of life science were recognized by both its many partners and the City of Philadelphia at the BIO International Convention 2019. The BIO International Convention is hosted annually by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers …Read More >

Resource Type: Article
Resource Topic: Advanced Testing Clinical & Commercial Manufacturing

VIEW

Virus clearance validation across continuous capture chromatography

Abstract Multicolumn capture chromatography is gaining increased attention lately due to the significant economic and process advantages it offers compared with traditional batch mode chromatography. However, for wide adoption of this technology in clinical and commercial space, it requires scalable models for executing viral validation studies. In this study, viral validation studies were conducted under …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Multibillion-dollar race for gene therapy manufacturing

“Gene therapy, a promising therapeutic approach that corrects disease-causing genetic errors, has spurred an arms race among the world’s largest pharmaceutical companies. Novartis (NYSE: NVS) announced the acquisition of AxeVis for a whopping $8.7 billion in 2018. Roche (NASDAQOTH: RHHBY) agreed to acquire gene therapy developer Spark Therapeutics for $4.8 billion in early 2019. One week …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW